Navigation Links
D-cycloserine may improve behavioral therapy treatment for anxiety
Date:7/16/2008

Philadelphia, PA, July 16, 2008 Anxiety is a normal human response to stress, but in some, it can develop into a disabling disorder of excessive and irrational fears, such as obsessive-compulsive disorder, panic disorder, or posttraumatic stress disorder. Effective treatments are available and can involve either behavioral therapy or medications. Although "it makes intuitive sense that combining these two treatments would result in even better results," David Tolin, Ph.D. notes that has unfortunately not yet been the case and the majority of the evidence suggests that combined therapy is no more effective than behavior therapy alone, and in some cases can even be less effective. However, Dr. Tolin is one of the three authors on a meta-analysis scheduled for publication on June 15th in Biological Psychiatry, in which they evaluated a potentially important new treatment paradigm for anxiety.

Dr. Tolin explains the impetus behind their analysis: "Recently, several researchers have tried a radically different approach: instead of just throwing two effective monotherapies at the problem, they have instead looked at medications that specifically target the biological mechanisms that make psychotherapy work in the first place." John H. Krystal, M.D., Editor of Biological Psychiatry and another of the study's authors, adds that "there has now been a sufficient amount of research in this area to take a step back to look at the basic research conducted in animals and the initial clinical trials." This research effort has involved the addition of D-cycloserine, an old drug long approved by the U.S. Food and Drug Administration for the treatment of tuberculosis, to exposure-based fear treatment in animals and humans. The meta-analysis, a pooling of the published literature on this approach, provides evidence that D-cycloserine enhances the learning process in the brain, indicating that, unlike many other medications, it may improve the effectiveness of behavioral therapy.

There is a caveat, however, as the authors also discovered that tolerance may develop to this effect. Dr. Krystal comments that, if so, "it may be best used before therapy sessions to 'warm up the brain' and make it more responsive to the treatment sessions rather than as a daily treatment."

Dr. Tolin makes an additional, important observation regarding this line of work: "Another very exciting aspect of this work is that it's one of the few really good examples of translational research in psychiatry: taking basic science from the laboratory, in this case animal studies, and translating that research into useful interventions for humans." Although additional research is clearly necessitated, this confirmation of the effectiveness of D-cycloserine is a positive step forward in improving treatments for individuals suffering with anxiety disorders.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. Broad-based group of physicians calls for improvement in stroke treatment
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. Pill box organizers increase HIV patients adherence and improve viral suppression
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
7. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
8. Exercise and yoga improves quality of life in women with early-stage breast cancer
9. QI projects may -- or may not -- improve patient safety and outcomes
10. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 20, 2016 According to the 2016 ... increasing demand for affordable healthcare solutions as since the early ... rise. In countries like the US, the healthcare cost rose ... the consumer price index inflation rate stood at an average ... up to 3.62% during the same time period. This can ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented ... 8006)   The conclusions of the study point to ... with 90% of the m presenting duration ... two percent of the patients had clinical benefit.   ... Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients ...
Breaking Medicine Technology: